Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Entero Therapeutics ( (ENTO) ).
On February 3, 2025, Entero Therapeutics announced a significant restructuring of its Board of Directors. The company appointed Manpreet Uppal, Alson Niu, and Richard Joel Paolone as new directors, replacing Timothy Ramdeen, Alastair Riddell, and James Sapirstein. However, on February 5, 2025, Alson Niu resigned and was replaced by Eric Corbett. These changes are expected to impact the company’s governance structure, with the new directors bringing diverse expertise in capital markets, corporate finance, and legal matters.
More about Entero Therapeutics
YTD Price Performance: -15.38%
Average Trading Volume: 202,419
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.61M
For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.